ROLE OF PHYSICAL ACTIVITY IN THE PREVENTION AND MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE

MA SHAH; AA KHAN; . NOOR; S AHMAD

doi:10.54112/bcsrj.v2023i1.499

Authors

MA SHAH 1Department of Medicine, PAF Teaching Hospital Mushaf Sargodha, Pakistan
AA KHAN 2Department of Radiology, Khyber Teaching Hospital Peshawar, Pakistan
. NOOR 3Department of Gastroenterology and Hepatology, Combined Military Hospital Lahore, Pakistan
S AHMAD Department of Emergency, District Head Quarter Hospital Swabi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.499

Keywords:

Non-alcoholic fatty liver disease, Physical activity, Metabolic Equivalent Task, Fibrosis, Liver health

Abstract

Non-alcoholic Hepatic Steatosis (NAFLD) is a major global cause of chronic liver disease. Its prevalence increases with the rise in metabolic syndrome components, primarily obesity and insulin resistance. The etiology of NAFLD is multifactorial, and recent studies suggest a "multiple hit" hypothesis that includes a combination of genetic, metabolic, and environmental factors. Lifestyle habits, including physical activity, play a significant role in its management. This study investigated the relationship between physical activity levels and the prevalence and severity of NAFLD in adults. A cross-sectional approach was used with a total of 250 participants. The participants were evenly divided into two groups: those diagnosed with NAFLD (n=125) and control subjects without NAFLD (n=125). Stratification was carefully executed to ensure equivalence in age, gender, and main co-morbidities to eliminate potential confounding variables. Among the 250 participants, with 125 individuals each in the NAFLD and control groups, no significant differences in age, BMI, or prevalence of co-morbidities such as diabetes and hypertension were observed. However, hepatic biochemical markers exhibited substantial differences between groups. ALT levels averaged 67.3 23.7 U/L for NAFLD participants compared to 24.2 ± 10.8 U/L in controls (p < 0.001); AST levels were at 54.8 ± 19.6 U/L for NAFLD versus 23.4 ± 8.9 U/L for controls (p < 0.001); GGT showed 89.2 ± 32.5 U/L in NAFLD individuals contrasting with 29.5 ± 13.4 U/L in controls (p < 0.001). Furthermore, the FIB-4 index was higher in the NAFLD cohort (2.4 ± 0.6) than in controls (1.3 ± 0.4; p < 0.001), and serum Albumin levels in NAFLD participants were 3.8 ± 0.5 g/dL, notably lower than the control's 4.5 ± 0.3 g/dL (p < 0.001). The study concludes that physical activity is inversely associated with the prevalence and severity of NAFLD. Regular physical activity may be a key strategy in preventing and managing NAFLD.

Downloads

Download data is not yet available.

References

Ainsworth, B. E., Haskell, W. L., Herrmann, S. D., Meckes, N., Bassett Jr, D. R., Tudor-Locke, C., Greer, J. L., Vezina, J., Whitt-Glover, M. C., and Leon, A. S. (2011). 2011 Compendium of Physical Activities: a second update of codes and MET values. Medicine & science in sports & exercise 43, 1575-1581.

Angulo, P. (2002). Non-alcoholic fatty liver disease. New England Journal of Medicine 346, 1221-1231.

Buzzetti, E., Pinzani, M., and Tsochatzis, E. A. (2016). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038-1048.

Clark, J. M., Brancati, F. L., and Diehl, A. M. (2002). Non-alcoholic fatty liver disease. Gastroenterology 122, 1649-1657.

Day, C. (2002). Pathogenesis of steatohepatitis. Best practice & research Clinical gastroenterology 16, 663-678.

Ekelund, U., Steene-Johannessen, J., Brown, W. J., Fagerland, M. W., Owen, N., Powell, K. E., Bauman, A., and Lee, I.-M. (2016). Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women. The lancet 388, 1302-1310.

Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., and Hultcrantz, R. (2015). Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up. Hepatology 61, 1547-1554.

Estes, C., Razavi, H., Loomba, R., Younossi, Z., and Sanyal, A. J. (2018). Modeling the epidemic of non-alcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123-133.

Jetté, M., Sidney, K., and Blümchen, G. (1990). Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. Clinical cardiology 13, 555-565.

Keating, S. E., Hackett, D. A., George, J., and Johnson, N. A. (2012). Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of hepatology 57, 157-166.

Lee, I.-M., Shiroma, E. J., Lobelo, F., Puska, P., Blair, S. N., and Katzmarzyk, P. T. (2012). Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. The lancet 380, 219-229.

Lonardo, A., Byrne, C., Caldwell, S., Cortez‐Pinto, H., and Targher, G. (2016). Global epidemiology of non-alcoholic fatty liver disease: meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 1388-1389.

Loomba, R., and Sanyal, A. J. (2013). The global NAFLD epidemic. Nature reviews Gastroenterology & hepatology 10, 686-690.

Mokdad, A. A., Lopez, A. D., Shahraz, S., Lozano, R., Mokdad, A. H., Stanaway, J., Murray, C. J., and Naghavi, M. (2014). Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC medicine 12, 1-24.

Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., and Wing, R. R. (2010). Randomized controlled trial testing the effects of weight loss on non-alcoholic steatohepatitis. Hepatology 51, 121-129.

Rinella, M. E. (2015). Non-alcoholic fatty liver disease: a systematic review. Jama 313, 2263-2273.

Samuel, V. T., and Shulman, G. I. (2012). Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852-871.

Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., Sanyal, A. J., and Network, N. C. R. (2009). Comparison of noninvasive markers of fibrosis in patients with non-alcoholic fatty liver disease. Clinical gastroenterology and hepatology 7, 1104-1112.

Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., Sulkowski, M. S., Torriani, F. J., Dieterich, D. T., and Thomas, D. L. (2006). Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43, 1317-1325.

Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., and Bugianesi, E. (2018). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature reviews Gastroenterology & hepatology 15, 11-20.